Abstract: Objective To investigate the clinical effect of Doxofylline, Roxithromycin and Eucalyptol Enteric Soft Capsule in the combination treatment of bronchiectasis.Methods The clinical data of 60 patients with bronchiectasis admitted to our hospital from February 2016 to May 2018 were analyzed.They were divided into the control group and the observation group by the random paper strip, 30 cases in each group.The patients in the control group were treated with low dose Roxithromycin, while the patients in the observation group were treated with Doxofylline, Roxithromycin and Eucalyptol Enteric Soft Capsule.The lung function, dyspnea score and imaging score of the patients with bronchiectasis before and after treatment were compared.The clinical efficacy in the two groups was observed.Results There were no significant differences in the first second forced expiratory volume (FEV1), forced vital capacity (FVC), peak expiratory flow (PEF), dyspnea score or imaging score between the two groups before treatment (P>0.05).After treatment,the values of FEV1,FVC and PEF in the two groups were higher than those before treatment, and the dyspnea and imaging scores were lower than those before treatment, with statistical significance (P<0.05).Compared with the control group, the FEV1, FVC and PEF of the observation group were higher, and the dyspnea and imaging scores were lower ,with statistical significance (P<0.05).The total effectiveness rate of clinical treatment of bronchiectasis patients in the observation group was higher than that in the control group, with statistical significance (P<0.05).Conclusion The combination of Doxofylline, Roxithromycin, and Eucalyptol Enteric Soft Capsule in the treatment of patients with bronchiectasis can remarkably improves the lung function, reduces the dyspnea and imaging scores, and is worthy of clinical application and promotion.
[J]. 中国当代医药, 2019, 26(12): 88-91.
CHEN Yi ;DENG Hong-wei. Clinical effect of combination of Doxofylline, Roxithromycin and Eucalyptol Enteric Soft Capsule in the treatment of bronchiectasis. 中国当代医药, 2019, 26(12): 88-91.
Altenburg J,de Graaff CS,Stienstra Y,et al.Effect of azithromycin maintenance treatment on infectious exacerbations among patients with non-cystic fibrosis bronchiectasis:the BAT randomized controlled trial[J].JAMA,2013,309(12):1251-1259.
Shi ZL,Peng H,Hu XW,et al.Effectiveness and safety of macrolides in bronchiectasis patients:a meta-analysis and systematic review[J].Pulm Pharmacol Ther,2014,28(2):171-181.
Porcel JM,Pardina M,Bielsa S,et al.Derivation and validation of a CT scan scoring system for discriminating malignant from benign pleural effusions[J].Chest,2015,147(2):513-519.
Mehmet K,Aydin K,Suat K,et al.Evaluation of effects of bronchiectasis on bronchial artery diameter with multidetector computed tomography[J].Acta Radiol,2014,55(2):171-178.
Singleton RJ,Valery PC,Morris P,et al.Indigenous children rom three countries with non-cystic fibrosis chronic suppurative lung disease/bronchiectasis[J].Pediatr Pulm,2014,49(2):189-200.
[11]
Nawa T,Yokozawa M,Takamuro M,et al.Plastic bronchitis developing 5 years after fontan procedure in a girl with kartagener′s syndrome[J].Ediatr Cardiol,2012,33(5):846-849.
Begrow F,Bckenholt C,Ehmen M,et al.Effect of myrtol standardized and other substances on the respiratory tract:ciliary beat frequency and mucociliary clearance as parameters[J].Adv Ther,2012,29(4):350-358.